TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Varenicline + Patch Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline Only Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline + Patch Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch | Arm Label: Varenicline Only Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration | Intervention Type: OTHER; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: OTHER; Name: Placebo Pill; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Standard Duration
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Arm Label: The STOP intervention; Type: EXPERIMENTAL; Interventions: Other: The STOP intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: The STOP intervention; Assigned to Arm(s): The STOP intervention | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Nicotine E-Cigarette and Counseling; Type: EXPERIMENTAL; Interventions: Other: Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Non-Nicotine E-Cigarette and Counseling; Type: OTHER; Interventions: Other: Non-Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Counseling; Type: OTHER; Interventions: Behavioral: Counseling | Intervention Type: OTHER; Name: Nicotine E-Cigarette; Assigned to Arm(s): Nicotine E-Cigarette and Counseling | Intervention Type: OTHER; Name: Non-Nicotine E-Cigarette; Assigned to Arm(s): Non-Nicotine E-Cigarette and Counseling | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Counseling, Nicotine E-Cigarette and Counseling, Non-Nicotine E-Cigarette and Counseling
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
D: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: NOT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: NOT program | Arm Label: NOT controls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: NOT controls | Arm Label: KB intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Kicking Butts intervention | Arm Label: KB controls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: KB controls | Intervention Type: BEHAVIORAL; Name: NOT program; Assigned to Arm(s): NOT Intervention | Intervention Type: BEHAVIORAL; Name: NOT controls; Assigned to Arm(s): NOT controls | Intervention Type: BEHAVIORAL; Name: Kicking Butts intervention; Assigned to Arm(s): KB intervention | Intervention Type: BEHAVIORAL; Name: KB controls; Assigned to Arm(s): KB controls
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CBST | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + CBST; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Pediatric Practice-Based Smoking Intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Arm Label: Nicotine Replacement Therapy Responder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patches | Arm Label: Pre-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit) | Arm Label: Pre-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Pre-Quit) | Arm Label: Pre-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Pre-Quit) | Arm Label: Post-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit) | Arm Label: Post-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Post-Quit) | Arm Label: Post-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Post-Quit) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Replacement Therapy Responder | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Nicotine
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Behavioral: Standard Care only | Arm Label: 2; Type: N/A; Interventions: Behavioral: Dental Hygienist provided counseling + Brief Questionnaire | Arm Label: 3; Type: N/A; Interventions: Behavioral: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire | Intervention Type: BEHAVIORAL; Name: Standard Care only; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Dental Hygienist provided counseling + Brief Questionnaire; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire; Assigned to Arm(s): 3
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Telephone quitline; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief Summary: This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
Brief Summary: The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure. Vascular filling may also have an impact on tolerability of enteral nutrition. The earliness and quantity of calories provided by enteral nutrition may have an impact on morbidity and mortality. This study will asses the effects of volume expansion on hemodynamics and tolerability of enteral nutrition in patients with severe sepsis. A Data Monitoring Committee will review regularly safety data of the study.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloids | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Colloids | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2
B: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
C: Arm Label: 7.5% hypertonic saline/6% dextran (HSD); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD) | Arm Label: 7.5% hypertonic saline (HS); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline (HS) | Arm Label: 0.9% normal saline (NS); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline (NS) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD); Assigned to Arm(s): 7.5% hypertonic saline/6% dextran (HSD) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline (HS); Assigned to Arm(s): 7.5% hypertonic saline (HS) | Intervention Type: DRUG; Name: 0.9% Normal Saline (NS); Assigned to Arm(s): 0.9% normal saline (NS)
D: Intervention Type: DRUG; Name: HyperHAES vs. RA-solution/NaCl; Assigned to Arm(s): N/A

Answer: B